Search

Now showing items 1-7 of 7

Catheter Ablation of Atrial Fibrillation in U.S. Community Practice--Results From Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).

Chang, P; Gersh, Bernard John; Holmqvist, Fredrik Nils; Hong, SJ; Kowey, Peter R; Naccarelli, GV; ORBIT-AF Investigators; ... (12 authors) (J Am Heart Assoc, 2015-05-21)

BACKGROUND: The characteristics of patients undergoing atrial fibrillation (AF) ablation and subsequent outcomes in community practice are not well described. METHODS AND RESULTS: Using the Outcomes Registry for Better Informed ...

Sex-based differences in outcomes after percutaneous coronary intervention for acute myocardial infarction: a report from TRANSLATE-ACS.

Hess, Connie Ng; McCoy, LA; Duggirala, HJ; Tavris, DR; O'Callaghan, K; Douglas, Pamela Susan; Peterson, Eric David; ... (8 authors) (J Am Heart Assoc, 2014-02-07)

BACKGROUND: Data regarding sex-based outcomes after percutaneous coronary intervention (PCI) for myocardial infarction are mixed. We sought to examine whether sex differences in outcomes exist in contemporary practice. METHODS ...

Contemporary trends and predictors of postacute service use and routine discharge home after stroke.

Prvu Bettger, Janet; McCoy, L; Smith, EE; Fonarow, GC; Schwamm, LH; Peterson, Eric David (J Am Heart Assoc, 2015-02-23)

BACKGROUND: Returning home after the hospital is a primary aim for healthcare; however, additional postacute care (PAC) services are sometimes necessary for returning stroke patients to their pre-event status. Recent trends ...

Perception Versus Actual Performance in Timely Tissue Plasminogen Activation Administration in the Management of Acute Ischemic Stroke.

Britz, GW; Constable, M; Cox, M; Fonarow, GC; Lin, CB; Olson, DaiWai M; Peterson, Eric David; ... (9 authors) (J Am Heart Assoc, 2015-07-22)

BACKGROUND: Timely thrombolytic therapy can improve stroke outcomes. Nevertheless, the ability of US hospitals to meet guidelines for intravenous tissue plasminogen activator (tPA) remains suboptimal. What is unclear is ...

Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.

Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, Bernard John; Holmes, DaJuanicia; Hylek, EM; ... (15 authors) (J Am Heart Assoc, 2013-11-25)

BACKGROUND: Dabigatran is a novel oral anticoagulant approved for thromboprophylaxis in atrial fibrillation. Adoption patterns of this new agent in community practice are unknown. METHODS AND RESULTS: We studied patterns ...

Racial differences in the prevalence and outcomes of atrial fibrillation among patients hospitalized with heart failure.

Fonarow, GC; Get With the Guidelines Steering Committee and Hospitals; Hernandez, Adrian Felipe; Liang, L; Peterson, Eric David; Piccini, Jonathan Paul Sr; Thomas, Kevin Lindsey; ... (8 authors) (J Am Heart Assoc, 2013-09-26)

BACKGROUND: The intersection of heart failure (HF) and atrial fibrillation (AF) is common, but the burden of AF among black patients with HF is poorly characterized. We sought to determine the prevalence of AF, characteristics, ...

Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry.

Delemos, J; Peng, SA; Peterson, Eric David; Roe, Matthew Todd; Sherwood, MW; Wang, TY; Wiviott, SD (J Am Heart Assoc, 2014-04-14)

BACKGROUND: P2Y12 antagonist therapy improves outcomes in acute myocardial infarction (MI) patients. Novel agents in this class are now available in the US. We studied the introduction of prasugrel into contemporary MI practice ...